Drugs / HEC68498
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04324372 | Feb 2019 → Feb 2021 | refractory malignant neoplasm | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03502902 | Apr 2018 → Mar 2019 | idiopathic pulmonary fibrosis | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEC68498 | “HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR).” NCT03502902 ↗ |
| Action | Inhibit | “highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR)” NCT03502902 ↗ |
| Route | Oral | “Single Oral Dose” NCT03502902 ↗ |